If you're interested in receiving 30 days of COMPLIMENTARY daily real-time updates delivered to your inbox each morning, simply click here. Additionally, if if you are interested in learning more about The Future of Spine Enabling Technology for 2023, click here to read the article.
New Products:
Orthofix noted that the Company launched the Lattus Lateral Access System and the Fathom Pedicle-Based Retractor System during Q123, which both address what the Company estimated to be a $1.8B MIS spine market.
Globus Medical has announced FDA approval of REFLECT Scoliosis Correction System, the company's first humanitarian device. The non-fusion system, using a flexible cord instead of rigid metal rods, corrects scoliosis in young pts while preserving motion and allowing for growth.
Patents:
NuVasive was issued US Patent “Method And Apparatus For Performing Spine Surgery” describing hyper-lordotic lateral implants along with associated methods for implantation and instruments. 11,647,999F
Globus Medical’s US Patent Application “IMPLANTABLE SYSTEMS, DEVICES AND RELATED METHODS” was published describing a low profile frame and spacer system for inserting into a disc space. 20230149181
DMedos Int’l SARL was granted US Patent “Implant Receivers And Connectors With Grip Grooves For Rod Fixation” describing implant receivers and connectors w/ grip grooves for improved rod fixation. 11,653,953
Studies:
A study 105 pts investigated the influence of the preoperative L5-S1 disc status on the clinical outcome of LLIFs, concluding that preop L5-S1 disc degeneration does not seem to impact the final clinical outcomes after LLIF. Eur Spine J
This 12K-pt review analyzed adult spinal deformity surgery performed by neuro or ortho surgeons. Neurosurgeons operated on older, more comorbid patients, utilizing shorter-segment fixation and navigation and robotics techniques. Both specialties had similar complication rates. SJ
At one yr f/up, a 53-pt study found 43% of elderly patients achieved a return to sports (RTS) after spinal surgery. More than half of patients returned to sports activities less than 2x/wk and reported high satisfaction. The RTS rate was 50% for lumbar and 35.3% for cervical spine. OJSM
Deals/Financing:
CarboFix recently announced it has been awarded a national pricing agreement w/ CHRISTUS Health which spans 60+ hospitals and 175 clinics in the South Central and Western US. Under the agreement CHRISTUS Health will have access to CarboFix's entire trauma product portfolio.
Assure Holdings - Underwritten Public Offering
Assure Holdings, a provider of intraop neuromonitoring, announced an underwritten public offering of 5MM shares of its common stock at a public offering price of $1.20 per share. The pre-funded warrants will be immediately exercisable at $0.001 or on a cashless basis.
Clinical/Regulatory:
A multi-center observational study of 10,000 patients that aimed to understand, analyze and compare the treatment and prognosis of pts w/ degenerative spine diseases and to construct a risk warning model and a decision-making system was completed on May 22, 2023. Clinicaltrials.org
Aurora Spine reported that its Dexa-C received IRB approval to commence a multicenter, multi-year study in Q123. Aurora Q123 Earnings Statement
LDGraft* - Locate Bio*
Cresco Spine announced that it has received Breakthrough Device designation for its Spring Distraction System, a new approach to growth modulation in the treatment of scoliosis. The BDD will allow for greater WW adoption of the system for those w / early-onset scoliosis. LinkedIn
Markets:
CG views spine as a customer-centric market driven by surgeon preference, which offers an arena where focused pure-play operators keyed in on innovation and clinical solutions can continue to drive share gains and thus predicts growth for players like ATEC. CG Flash Update
Revenues:
For Q4FY23, MDT reported US Cranial & Spinal Technologies (CST) revenue of $855M, up +1.5 % as reported. FY23 CST US revenue totaled $3.26B, up +2.8% as reported. MDT Q4FY23 Earnings Release
For Q123, Orthofix reported WW Spinal Implant and Enabling Technologies revenue to be $60.9MM, up +128% from Q122, driven largely by the company’s merger with SeaSpine. OFIX Q123 Form 10-Q
Aurora Spine*
In its final H122 report, Medacta reported Spine revenue increased +19.4% to ~$19.9MM (€19.8), +16% CC driven by the expansion of MIS Platform and MySpine offering. Medacta Final H122 Earnings Report
*These links can only be viewed by SmartTRAK subscribers. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.